Table 1.

Direct-acting antivirals (clinical development status in parenthesis)

NS3/4A Protease inhibitors	NS5A inhibitors	Polymerase inhibitors
		NIs	NNIs
Telaprevir (approved)	Daclatasvir (approved)	Sofosbuvir (approved)	Dasabuvir (phase 3)
Boceprevir (approved)	Ledipasvir (phase 3)	Mericitabine (phase 2)	BMS-791325 (phase 3)
Simeprevir (approved)	Ombitasvir (approved)	VX-135 (phase 2)	PPI-383 (phase 1)
Asunaprevir (phase 3)	GS-5816 (phase 2)		GS-9669 (phase 2)
Danoprevir (phase 3)	ACH-2928 (phase 1)		TMC647055I (phase 2)
Paritaprevir (approved)	ACH-3102 (phase 2)		VX-222 (phase 2)
Vaniprevir (phase 3)	PPI-668 (phase 2)
Sovaprevir (phase 2)	PPI-461 (phase 1)
MK-5172 (phase 3)	GSK2336805 (phase 2)
ACH-2684 (phase 2)	Samatasvir (phase 2)
Narlaprevir (phase 2)	MK-8742 (phase 3)
Vedroprevir (phase 2)	BMS-824393 (phase 2)

NI: Nucleoside inhibitors; NNIs: Non-nucleoside inhibitors.